PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism
Recruiting now · Not applicable
Conditions studied: Primary Aldosteronism, Secondary Hypertension, Aldosterone-Producing Adenoma, Idiopathic Hyperaldosteronism, Adrenalectomy
In brief
This study is a randomized controlled trial to assess the clinical utility of gallium-68 pentixafor PET/CT in the management of primary aldosteronism (PA). We aim to evaluate whether the addition of 68Ga-pentixafor PET/CT to standard adrenal venous sampling (AVS) improves surgical outcomes in patients with unilateral PA.
Key facts
- Study ID
- NCT07027254
- Run by
- Seoul National University Hospital
- People needed
- 90
- Starts
- 2025-06-25
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2025-06-18
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥19 years
- Diagnosed with PA per 2016 Endocrine Society guidelines
- Underwent adrenal CT
- Signed informed consent
You may not qualify if…
- Women who are pregnant, breastfeeding, or may become pregnant
- Individuals who refuse to undergo surgery
- Individuals for whom 68Ga-Pentixafor PET/CT, 11C-Metomidate PET/CT, or adrenal venous sampling (AVS) is not feasible or is refused due to underlying conditions
- Individuals who refuse or experience adverse effects from dexamethasone premedication required for 11C-Metomidate PET/CT
- Individuals with a history of abdominal open surgery or retroperitoneal surgery on the same side as the planned adrenalectomy
- Any individual deemed unsuitable for the study at the discretion of the investigator
Where it is running
- Samsung Medical Center — Seoul, Gangnam-gu, South Korea (enrolling)
- Seoul National University Hospital — Seoul, Jongno-gu, South Korea (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.